. | Total cohort . | eGFR (ml/min per 1.73 m2) . | . | . | . | P for trend . | |||
---|---|---|---|---|---|---|---|---|---|
. | . | ≥90 . | 60–89 . | 30–59 . | 15–29 . | . | |||
n | 4,421 | 2,257 | 1,636 | 457 | 71 | ||||
All-cause mortality (%) | 2.5 (2.0–2.9) | 1.2 (0.8–1.7) | 2.6 (1.9–3.4) | 5.5 (3.3–7.6) | 18.3 (9.1–27.5) | <0.001 | |||
Cardiovascular end points (%) | 4.8 (4.2–5.5) | 2.6 (2.0–3.3) | 5.4 (4.3–6.5) | 10.3 (7.5–13.1) | 25.4 (15.0–35.7) | <0.001 | |||
Renal end points (%) | 4.8 (4.1–5.4) | 1.7 (1.1–2.2) | 3.0 (2.1–3.8) | 16.5 (12.9–20.1) | 68.2 (56.6–79.7) | <0.001 | |||
Composite end points (%) | 9.6 (8.7–10.5) | 5.0 (4.1–6.0) | 9.0 (7.6–10.5) | 23.9 (19.8–28.0) | 75.8 (65.1–86.4) | <0.001 |
. | Total cohort . | eGFR (ml/min per 1.73 m2) . | . | . | . | P for trend . | |||
---|---|---|---|---|---|---|---|---|---|
. | . | ≥90 . | 60–89 . | 30–59 . | 15–29 . | . | |||
n | 4,421 | 2,257 | 1,636 | 457 | 71 | ||||
All-cause mortality (%) | 2.5 (2.0–2.9) | 1.2 (0.8–1.7) | 2.6 (1.9–3.4) | 5.5 (3.3–7.6) | 18.3 (9.1–27.5) | <0.001 | |||
Cardiovascular end points (%) | 4.8 (4.2–5.5) | 2.6 (2.0–3.3) | 5.4 (4.3–6.5) | 10.3 (7.5–13.1) | 25.4 (15.0–35.7) | <0.001 | |||
Renal end points (%) | 4.8 (4.1–5.4) | 1.7 (1.1–2.2) | 3.0 (2.1–3.8) | 16.5 (12.9–20.1) | 68.2 (56.6–79.7) | <0.001 | |||
Composite end points (%) | 9.6 (8.7–10.5) | 5.0 (4.1–6.0) | 9.0 (7.6–10.5) | 23.9 (19.8–28.0) | 75.8 (65.1–86.4) | <0.001 |
Data are percent (95% CI). Cardiovascular end points were defined as hospitalizations due to ischemic heart disease, congestive heart failure, stroke, and revascularization procedures. Renal end points were defined as reduction in eGFR by >50% or progression to eGFR <15 ml/min per 1.73 m2 (stage 5) or renal dialysis or death secondary to renal causes. Composite end points were that of all-cause mortality and cardiovascular and renal end points.